444805-28-1

Basic information

• Product Name: CMX 001
• Synonyms: Brincidofovir (CMX001);Brincidofovir;CMX001(Brincidofovir);(S)-[2-(4-amino-2-oxo-1,2-dihydro-1-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methylphosphonic acid 3-(hexadecyloxy)propyl monoester;[[(S)-2-(4-Amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)ethoxy]methyl]phosphonic acid mono[3-(hexadecyloxy)propyl] ester;CMX 001;HDP-cidofovir;Hexadecyloxypropyl-cidofovir
• CAS NO: 444805-28-1
• Molecular Formula: C27H52N3O7P
• Molecular Weight: 561.691441
• Mol File: 444805-28-1.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 688.6±65.0 °C(Predicted)
• Appearance: /
• Density: 1.17±0.1 g/cm3(Predicted)
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: DMSO (Slightly, Sonicated), Ethanol (Slightly, Heated, Sonicated), Methanol (Sli
• PKA: 2.40±0.10(Predicted)
• Stability: Hygroscopic
• CAS DataBase Reference: CMX 001(CAS DataBase Reference)
• NIST Chemistry Reference: CMX 001(444805-28-1)
• EPA Substance Registry System: CMX 001(444805-28-1)

Safety Data

• Hazardous Substances Data: 444805-28-1(Hazardous Substances Data)

Usage

Uses

Brincidofovir is an antiviral inhibitor, working against BK polymavirus replication in primary human urothelial cells. Cytostatic, cytotoxic agent.

Biological Activity

cmx001 is a broad spectrum antiviral agent [1].cmx001 has been reported to be active in vitro against a broad range of viruses from all five families of dsdna viruses infecting human with ec50 values of 0.02μm, 0.0004μm, 17μm , 0.045μm and 0.07μm for adenovirus, herpesvirus, papillomavirus, polyomavirus and orthopoxvirus, respectively. in addition, cmx001 has been revealed to arrest disease progression by inhibiting viral dna replication and thereby reducing viral burden. apart from these, initial studies has been demonstrated the efficacy of cmx001 for pre-exposure and post-exposure prophylaxis in mouse, rabbit, cynomolgus monkeys and human [1].

references

[1]lanier r1, trost l, tippin t, lampert b, robertson a, foster s, rose m, painter w, o'mahony r, almond m, painter g.development of cmx001 for the treatment of poxvirus infections. viruses. 2010 dec; 2(12):2740-2762.

Upstream product

• 1362039-08-4 phosphonic acid [[(S)-2-(4-amino-2-oxo-1(2H)-pyrimidinyl)-1-(hydroxymethyl)-2-(triphenylmethoxy)ethyl]methyl]mono[3-(hexadecyloxy)propyl]ester 
• 132336-30-2 (S)-N-1-[(2-hydroxy-3-triphenylmethoxy)propyl]cytosine 
• 912635-37-1 cyclic cidofovir DCMC salt 
• 864068-45-1 {[3-(hexadecyloxy)propoxy](hydroxy)phosphoryl}methyl tosylate 
• 864068-43-9 1-(S)-[3-trityloxy-2-hydroxypropyl]-N⁴-monomethoxytritylcytosine 
• 20779-14-0 methanesulfonic acid hexadecyl ester 
• 36653-82-4 1-Hexadecanol 
• 864068-46-2 N₄-monomethoxytrityl-O₃'-trityl-cidofovir, hexadecyloxypropyl ester 
• 23377-40-4 3-hexadecyloxy-1-propanol 
• 113852-37-2 cidofovir 
• 127757-45-3 cyclic cidofovir 
• 126614-26-4 1-(hexadecyloxy)-3-bromopropane 
• 343248-25-9 1-O-hexadecyloxypropyl cyclic cidofovir 

Relevant articles and documents

Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir

The nucleotide phosphonates cidofovir (CDV) and cyclic cidofovir (cCDV) are potent antiviral compounds when administered parenterally but are not well absorbed orally. These compounds have been reported to have activity against orthopoxvirus replication i

Morphic forms of hexadecyloxypropyl-phosphonate esters and methods of synthesis thereof

The disclosure describes methods of synthesis of phosphonate ester compounds. The methods according to the disclosure allow for large-scale preparation of phosphonate ester compounds having high purity and stability. Also disclosed are morphic forms of ph

COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF POXVIRUS INFECTIONS

The present application provides methods and compositions for combination therapy with antiviral compounds for the treatment of poxvirus infections, such as orthopox virus infections. In one embodiment, a method of treatment of a poxvirus infection is provided that comprises administering to a host in need thereof cidofovir, cyclic cidofovir, or a salt, ester, or prodrug thereof in combination or alternation with at least a second anti-poxvirus agent. The second anti-poxvirus agent is, for example, a biologic, such as a pegylated interferon.

METHODS FOR PREPARATION OF NUCLEOSIDE PHOSPHONATE ESTERS

A process is provided for the preparation of lipophilic monoesters of formula (3) and their stereoisomers. The process includes the steps of esterification of a phosphonate with a lipophilic alcohol, then allowing the resultant product to react with a sui